SODIUM BICARBONATE AND CHRONIC KIDNEY DISEASE PROGRESSIO
Not Applicable
- Conditions
- Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)Health Condition 2: N184- Chronic kidney disease, stage 4 (severe)
- Registration Number
- CTRI/2022/02/039964
- Lead Sponsor
- INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH KOLKATA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
CKD STAGE 3 AND 4
SERUM BICARBONATE LESS THAN 22 MMOL/L
STABLE CLINICAL CONDITION AS ASSESSED BY TREATING PHYSICIA
Exclusion Criteria
MALIGNANCY
MORBID OBESITY
COGNITIVE IMPAIRMENT
SEPSIS
POORLY CONTROLLED BLOOD PRESSURE
OVERT CONGESTIVE HEART FAILURE
AUTOIMMUNE DISEASE
LIMB AMPUTATION
POLYCYSTIC KIDNEY DISEASE
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PROPORTION OF PATIENTS HAVING EGFR DECLINE MORE THAN 5 ML/MIN OR END STAGE KIDNEY DISEASETimepoint: 12 MONTHS
- Secondary Outcome Measures
Name Time Method CHANGES IN NUTRITIONAL STATUS <br/ ><br>PROPORTION OF PATIENTS WITH ADVERSE EVENTSTimepoint: 12MONTHS
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie sodium bicarbonate's effect on CKD stage 3 and 4 progression in CTRI/2022/02/039964?
How does sodium bicarbonate therapy compare to standard-of-care treatments for N183/N184 CKD in clinical trials?
Which biomarkers correlate with response to sodium bicarbonate in slowing N183/N184 CKD progression?
What adverse events are associated with sodium bicarbonate in CKD stages 3 and 4, and how are they managed?
Are there combination therapies or alternative alkalinizing agents for CKD progression similar to CTRI/2022/02/039964's approach?